Standard BioTools Inc expected to post a loss of 7 cents a share - Earnings Preview
Standard BioTools Inc (LAB) is projected to report a loss of 7 cents per share in its upcoming earnings announcement. This information is based on an earnings preview from Refinitiv. The article provides a brief outlook on the company's expected financial performance.
Standard BioTools (LAB) Expected to Announce Quarterly Earnings on Tuesday
Standard BioTools (LAB) is set to release its Q4 2025 earnings after market close on Tuesday, February 24th, 2026. Analysts predict an EPS of ($0.03) and revenue of $18.5 million. The company has seen recent insider buying, with Casdin Partners acquiring 150,000 shares in December and institutional investors also adjusting their stakes, while analysts have a consensus "Reduce" rating with a $1.35 price target.
Standard BioTools Inc. (LAB) Stock Analysis: Unpacking a 39.64% Potential Upside in the Healthcare Sector
Standard BioTools Inc. (LAB), a medical devices company specializing in proteomics and genomics, shows a potential upside of 39.64% despite current financial challenges. Trading at $1.11, the stock is below its moving averages, with a low RSI suggesting it might be oversold. While the company faces revenue decline, negative EPS, and significant free cash flow issues, its innovative technological platforms and cautiously optimistic analyst ratings indicate long-term growth potential for risk-tolerant investors.
Standard BioTools Inc.'s (NASDAQ:LAB) Popularity With Investors Under Threat As Stock Sinks 27%
Standard BioTools Inc. (NASDAQ:LAB) has seen its stock drop 27% in the last month, contributing to an 11% decline over the past year. Despite a strong prior revenue growth of 80% last year and 55% over three years, analysts predict a 21% annual revenue decline for the next three years, contrasting with an expected 7.7% industry growth. This raises concerns about the company's price-to-sales ratio, which is currently similar to the industry median, suggesting investors might be overlooking future revenue declines.
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after the U.S. market closes. The company specializes in providing standardized next-generation technologies, including mass cytometry and microfluidics, to support biomedical research. They work with various laboratories globally, focusing on translational and clinical research.
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after the U.S. market closes. The company specializes in next-generation technologies for biomedical research, focusing on mass cytometry and microfluidics to support the development of medicines. Standard BioTools works with academic, government, pharmaceutical, and biotechnology organizations to advance translational and clinical research.
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after the U.S. market closes. The company, which provides essential next-generation technologies for biomedical research, focuses on delivering reliable insights in health and disease using mass cytometry and microfluidics. Standard BioTools partners with academic, government, pharmaceutical, and biotechnology laboratories worldwide to advance research in areas like oncology and immunology.
Standard BioTools Strengthens Balance Sheet with Major Divestiture
Standard BioTools has completed the divestiture of SomaLogic to Illumina for $350 million, significantly boosting its cash reserves to approximately $550 million with potential for an additional $75 million in earnouts and long-term royalty fees. This strategic move aims to strengthen the company's financial position, enable a focus on core operations, and provide flexibility for strategic acquisitions, following strong operational performance in 2025. Investors are awaiting the detailed Q4 and full-year 2025 financial results for further insights into the company's future outlook.
Standard BioTools completes sale of SomaLogic to Illumina for $350 million
Standard BioTools Inc. has completed the sale of SomaLogic to Illumina, Inc. for $350 million upfront, with potential for an additional $75 million in earnout payments. This acquisition strengthens Illumina's genomics market position and provides Standard BioTools with a 2% royalty on net revenues from SOMAmer-based NGS library preparation kits for 10 years. Standard BioTools emerges from this transaction in a strong financial position, aiming for positive adjusted EBITDA in 2026 and planning strategic acquisitions to drive growth.
Standard BioTools completes sale of SomaLogic to Illumina for $350 million
Standard BioTools Inc. has completed the sale of SomaLogic to Illumina, Inc. for an upfront cash payment of $350 million, with potential earnout payments up to an additional $75 million. This acquisition strengthens Illumina's position in the genomics market and provides Standard BioTools with royalty streams and a co-exclusive license for certain intellectual property. Standard BioTools estimates its post-transaction cash and cash equivalents at approximately $550 million, aiming for strategic acquisitions and positive adjusted EBITDA by 2026.
Standard BioTools Completes $350 Million Sale of SomaLogic to Illuminia
Standard BioTools has completed the $350 million sale of SomaLogic to Illumina. Separately, Unity Software reported impressive fourth-quarter financial results, with revenue increasing 35% year-over-year to $609 million, exceeding analyst estimates. However, Unity also reported a quarterly loss of 66 cents per share.
Standard BioTools completes sale of SomaLogic to Illumina for $350 million
Standard BioTools Inc. has finalized the sale of SomaLogic to Illumina, Inc. for $350 million upfront, with potential earnout payments up to $75 million. This acquisition bolsters Illumina's presence in the genomics market, while Standard BioTools aims to use its strengthened financial position to pursue strategic acquisitions and achieve positive adjusted EBITDA in 2026. This move is part of Standard BioTools' strategic transformation, making it more focused and financially robust.
Standard BioTools Completes Major Proteomics Business Divestiture
Standard BioTools (LAB) has finalized the sale of its aptamer-based and functional proteomics business, including SomaLogic, to Illumina for up to $425 million plus royalties. This divestiture allows Standard BioTools to focus on its mass cytometry and microfluidics operations, with approximately $550 million in cash. The company aims for inorganic growth and positive adjusted EBITDA in 2026, while analysts currently rate LAB stock as a Hold with a $1.50 price target.
Standard BioTools (LAB) Concludes Sale of SomaLogic for $425 Mil
Standard BioTools (LAB) has completed the sale of SomaLogic to Illumina for a total potential value of $425 million, including an upfront payment and contingent milestones. This strategic move aims to strengthen Standard BioTools' financial position and enable future mergers and acquisitions, despite the company currently facing significant financial challenges like declining revenue and operating margins. The company's financial health indicators, including an Altman Z-Score in the distress zone, highlight the need to address operational inefficiencies to improve investor confidence.
Standard BioTools Inc. Completes $350 Million Sale of SomaLogic to Illumina, Enhancing Financial Position for Growth Strategy
Standard BioTools Inc. has completed the sale of SomaLogic to Illumina for $350 million upfront, with potential total proceeds of up to $425 million. This transaction significantly strengthens Standard BioTools' financial position, providing approximately $550 million in cash and cash equivalents to fund future growth through disciplined mergers and acquisitions. The company aims to achieve positive adjusted EBITDA by 2026, marking a major step in its strategic transformation.
Standard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools Inc. has completed the sale of SomaLogic to Illumina for $350 million upfront cash, with potential earnouts up to $425 million and royalties. This transaction significantly strengthens Standard BioTools' financial position, providing approximately $550 million in cash and cash equivalents, which will be used to pursue inorganic growth strategies. The company aims for positive adjusted EBITDA in 2026, marking a major milestone in its strategic transformation.
Here's Why We're Not At All Concerned With Standard BioTools' (NASDAQ:LAB) Cash Burn Situation
Standard BioTools (NASDAQ:LAB) has demonstrated encouraging financial trends, with a 34% reduction in cash burn and an 80% increase in operating revenue over the last year. Despite burning US$98 million, the company holds US$195 million in cash, providing a two-year runway. Analysts project the company will reach breakeven before exhausting its cash, alleviating concerns about its cash burn.
Here's Why We're Not At All Concerned With Standard BioTools' (NASDAQ:LAB) Cash Burn Situation
Standard BioTools (NASDAQ:LAB) has a cash runway of about two years, based on its current cash reserves and burn rate. However, analysts predict the company will reach free cash flow break-even before exhausting its cash. The company's cash burn decreased by 34% last year, and its operating revenue grew by an impressive 80%, indicating healthy growth.
Here's Why We're Not At All Concerned With Standard BioTools' (NASDAQ:LAB) Cash Burn Situation
Standard BioTools (NASDAQ:LAB) has a cash runway of about two years based on its US$195m cash and US$98m annual burn, but analysts expect the company to break even before then. The company has reduced its cash burn by 34% and grown operating revenue by 80% over the last year, indicating healthy progress. Despite its cash burn relative to market capitalization being 17%, the company should be able to raise more capital if needed without significant trouble.
Standard BioTools (NASDAQ:LAB) shareholders have endured a 76% loss from investing in the stock five years ago
Standard BioTools (NASDAQ:LAB) shareholders have experienced a 76% loss over the past five years. Despite the significant share price drop, the company's revenue has grown at a modest 2.6% per year over the same period, while it continues to operate at a loss. The article suggests caution for investors due to the company's unprofitability and notes that sustained improvements in key metrics would be needed to generate enthusiasm.
Sumitomo Mitsui Trust Group Inc. Sells 773,708 Shares of Standard BioTools Inc. $LAB
Sumitomo Mitsui Trust Group Inc. reduced its stake in Standard BioTools Inc. by 12.5%, selling over 773,000 shares, though it still holds a significant position. The stock currently has an average "Reduce" rating from analysts with a target price of $1.35, despite some recent insider buying activity. Other institutional investors have also made changes to their holdings in the company.
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
Standard BioTools (LAB) reported a Q1 loss of $0.04 per share, aligning with Zacks Consensus Estimates, and exceeded revenue expectations with $40.8 million, despite a year-over-year decline. The company's stock has underperformed the S&P 500 year-to-date, and its current Zacks Rank is #3 (Hold), suggesting a market-line performance in the near future.
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Standard BioTools announced preliminary unaudited revenue results for Q4 and full year 2025, with combined company revenue expected to be approximately $56 million for Q4 and $185 million for the full year. CEO Michael Egholm highlighted steady execution, exceeding guidance, and progress toward profitability, with the sale of SomaLogic to Illumina expected to close in H1 2026, positioning the company for strategic M&A. The company anticipates reporting full financial results and 2026 outlook later this quarter.
Biotech company expects $550M cash to shop for more life science deals
Standard BioTools (LAB) announced preliminary, unaudited Q4 and full-year 2025 revenue results, expecting combined revenue of approximately $185 million for the full year. The company anticipates having about $550 million in cash after the projected close of the SomaLogic sale to Illumina in H1 2026, which it plans to use for disciplined M&A to build a diversified leader in life sciences. This news led to a significant positive market reaction, with LAB stock gaining over 20%.
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Standard BioTools Inc. announced preliminary unaudited revenues for Q4 and full year 2025, exceeding guidance with combined company revenue of approximately $185 million and continuing operations revenue of $85 million for the full year. The company emphasized its path toward profitability through streamlined operations and anticipates the sale of SomaLogic to Illumina to close in the first half of 2026, which will provide significant cash and strategic flexibility for future M&A. This positions Standard BioTools to build a diversified leader in life sciences.
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Standard BioTools Inc. announced preliminary unaudited revenue results for the fourth quarter and full year 2025, with combined company revenue projected at $185 million for the full year and $56 million for Q4. CEO Michael Egholm highlighted steady execution, exceeding guidance, and strategic actions taken to streamline operations and improve the cost structure. The company also looks forward to the closing of the SomaLogic sale to Illumina in the first half of 2026, which is expected to provide substantial cash and strategic flexibility for future M&A.
Standard BioTools Inc. (NASDAQ:LAB) Receives Average Recommendation of "Reduce" from Brokerages
Standard BioTools Inc. (NASDAQ:LAB) has received an average "Reduce" recommendation from analysts, with one sell and four hold ratings, and a consensus one-year target price of $1.35. Despite this, insiders have shown significant buying activity, acquiring 11.225 million shares in the last three months, bringing insider ownership to 23.16%. The company's stock currently trades at $1.27 with a market capitalization of $488.40 million.
Further weakness as Standard BioTools (NASDAQ:LAB) drops 15% this week, taking five-year losses to 80%
Standard BioTools Inc. (NASDAQ:LAB) has experienced a significant downturn, with its share price plummeting 80% over the last five years and a 15% drop this past week alone. While the company's revenue growth of 2.6% per year over the last five years is not impressive given its unprofitability, the market's strong negative reaction suggests a deeper disappointment. Investors are cautioned to ensure they are investing in a high-quality business before considering a purchase, especially given the company's continuous losses and unresolved challenges.
Further weakness as Standard BioTools (NASDAQ:LAB) drops 15% this week, taking five-year losses to 80%
Standard BioTools Inc. (NASDAQ:LAB) experienced a significant 15% drop this week, contributing to an 80% loss for shareholders over the last five years and a 29% decline in the past year. Despite a modest 2.6% annual revenue growth over five years, the company has not been profitable, leading to market disappointment and a rapidly declining share price. Investors may continue to be wary given the ongoing challenges and lack of profitability.
Further weakness as Standard BioTools (NASDAQ:LAB) drops 15% this week, taking five-year losses to 80%
Standard BioTools Inc. (NASDAQ:LAB) has experienced significant weakness, with its stock dropping 15% this past week and an alarming 80% over the last five years. Despite some revenue growth, the company remains unprofitable, leading to market disappointment and a rapidly declining share price. Investors are cautioned to consider the inherent risks and the lack of profitability before making investment decisions.
Standard BioTools: Outlook Still Murky (NASDAQ:LAB)
Standard BioTools is currently trading near its cash value following the sale of SomaScan, with Casdin Capital increasing its stake to 25%. While the company will receive $350M upfront and potential earnouts from Illumina for SomaScan, leading to $550M in cash post-transaction, its ongoing operations lack clear growth catalysts. This situation, combined with projected Adj. EBITDA breakeven in 2026 after divestiture and a 20% workforce reduction, indicates a murky outlook despite a recent rally in share price.
Standard BioTools Inc. (NASDAQ:LAB) Given Average Recommendation of "Reduce" by Analysts
Analysts have issued an average "Reduce" recommendation for Standard BioTools Inc. (NASDAQ:LAB), with one sell rating and four hold ratings, and a 12-month average target price of $1.35. Insider activity shows significant buying by Casdin Partners Master Fund, which acquired 7.55 million shares, increasing its stake. The company's stock is trading around $1.45 with a negative P/E ratio, while institutional investors hold a substantial portion of its shares.
Standard BioTools (NASDAQ:LAB) Director Casdin Partners Master Fund, L Purchases 75,000 Shares
Casdin Partners Master Fund, L, a director of Standard BioTools (NASDAQ:LAB), purchased 75,000 shares of the company's stock on December 3rd at an average price of $1.44, increasing its direct ownership to 71,950,000 shares. This transaction is part of a series of aggressive stock accumulations by Casdin, which has made multiple purchases between November 13th and December 4th. Standard BioTools currently trades at $1.44, with analysts holding a consensus "Reduce" rating and an average price target of $1.35.
Subdued Growth No Barrier To Standard BioTools Inc. (NASDAQ:LAB) With Shares Advancing 26%
Standard BioTools Inc. (NASDAQ:LAB) has seen a 26% share price increase recently, despite a 21% loss over the last year. The company's P/S ratio is 3.3x, similar to the industry average, but revenue growth is expected to decline by 21% per year over the next three years, contrasting with industry growth. This suggests that the current P/S ratio might not be justified given the negative growth forecasts.
Insider Buying: Standard BioTools (NASDAQ:LAB) Director Purchases 125,000 Shares of Stock
A director at Standard BioTools (NASDAQ:LAB), Casdin Partners Master Fund, L, recently purchased 125,000 shares of the company's stock for $1.42 per share, increasing its direct ownership to 71,875,000 shares. This transaction follows several other significant purchases by the same insider in late November and early December. Despite this insider buying, the stock trades at $1.44 with a market capitalization of $553.8 million, and analysts currently have a consensus "Reduce" rating with a $1.35 price target.
Subdued Growth No Barrier To Standard BioTools Inc. (NASDAQ:LAB) With Shares Advancing 26%
Standard BioTools Inc. (NASDAQ:LAB) has seen its shares rise 26% recently despite past losses. The company's P/S ratio of 3.3x is comparable to the industry average, but its future revenue growth is projected to decline significantly, contrasting with analyst expectations for industry growth. This raises questions about the sustainability of its current price levels given the poor revenue outlook.
Casdin funds buy Standard Biotools (LAB) shares for $502,570
Casdin Partners Master Fund and related entities purchased $502,570 worth of Standard Biotools Inc (NASDAQ:LAB) shares between December 2nd and December 4th, 2025. This investment aligns with InvestingPro's assessment of the stock being slightly undervalued, despite the company's strong current ratio being balanced against concerns about its cash burn. Standard Biotools recently announced a restructuring plan, including a 15% workforce reduction to improve operational efficiency.
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry
Molecular Instruments (MI) and Standard BioTools Inc. have announced a collaboration to integrate MI's HCR™ signal amplification with Standard BioTools' Imaging Mass Cytometry (IMC). This partnership aims to provide researchers with enhanced detection capabilities for multi-omic analysis, enabling more sensitive and robust spatial proteomics and transcriptomics applications. The collaboration will combine MI's advanced HCR technology with the high-plex imaging platform of IMC.
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry
Molecular Instruments (MI) and Standard BioTools Inc. have announced a strategic collaboration to integrate MI's HCR imaging platform with Standard BioTools' Imaging Mass Cytometry (IMC) technology. This partnership aims to develop next-generation IMC workflows that provide amplified multi-omic readouts for both RNA and protein targets in complex tissues. The collaboration is expected to enhance sensitivity and flexibility for researchers, enabling deeper insights into cellular processes.
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
Standard BioTools Inc. (NASDAQ: LAB) has announced that it will release its third-quarter 2025 financial results on Tuesday, November 4, 2025, after the U.S. market closes. The company, known for its essential next-generation technologies in biomedical research, aims to help develop better medicines faster. Its proprietary SomaScan, mass cytometry, and microfluidics technologies provide reliable insights into health and disease, supporting translational and clinical research worldwide.
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
Standard BioTools Inc. (NASDAQ: LAB) has announced that it will release its third-quarter 2025 financial results on Tuesday, November 4, 2025, after the U.S. market closes. The company specializes in next-generation technologies that aid biomedical researchers and provides solutions in health and disease using its proprietary SomaScan, mass cytometry, and microfluidics technologies. Standard BioTools works with academic, government, pharmaceutical, and other research laboratories worldwide.
Standard BioTools Reports Third Quarter 2025 Financial Results
Standard BioTools Inc. announced its financial results for the third quarter ended September 30, 2025, reporting $46.2 million in total combined company revenue and $19.6 million from continuing operations. The company is implementing a restructuring plan expected to yield over $40 million in annualized cost savings and projects achieving positive adjusted EBITDA in 2026. With $217.0 million in cash and cash equivalents, and an anticipated $550 million from the Illumina transaction in the first half of 2026, Standard BioTools plans to pursue inorganic growth through strategic M&A.
Standard BioTools Reports Third Quarter 2025 Financial Results
Standard BioTools Inc. announced financial results for Q3 2025, reporting $46.2 million in total revenue and $19.6 million from continuing operations. The company is implementing an operational restructuring plan expected to achieve over $40 million in annualized cost savings, aiming for positive adjusted EBITDA by 2026. With $217.0 million in cash and an anticipated $550 million from the upcoming Illumina transaction, Standard BioTools plans strategic M&A to fuel growth.
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
Standard BioTools Inc. announced it will release its third-quarter 2025 financial results on Tuesday, November 4, 2025, after the U.S. market closes. The company, known for its next-generation technologies in biomedical research, aims to help develop better medicines faster. Its proprietary technologies, including SomaScan, mass cytometry, and microfluidics, are used by leading academic, government, pharmaceutical, and biotechnology laboratories worldwide.
Standard BioTools (NASDAQ: LAB) schedules Q3 financial results release for Nov. 4
Standard BioTools (NASDAQ: LAB) announced it will publish its third-quarter 2025 financial results on Tuesday, November 4, 2025, after the U.S. market closes. The company, which provides essential technologies for biomedical researchers, noted that this announcement led to a 3.13% gain in its stock on the day the news was published, reflecting a moderate positive market reaction. Investors are advised to mark November 4, 2025, as the earnings release date.
Standard BioTools Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Standard BioTools, Inc. has experienced a Golden Cross, a technical indicator suggesting a potential bullish shift in momentum despite previous declines. The company has a one-year decline of 27.68% and a five-year drop of 83.61%, with year-to-date performance also lagging the S&P 500. This Golden Cross, coupled with mildly bullish technical indicators, prompts cautious monitoring by investors for a potential recovery.
Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
Standard BioTools Inc. (NASDAQ: LAB) announced that it will report its second-quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results and operational progress. Live audio of the webcast will be accessible on the Investor Relations page of the company’s website.
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Is Still On The Mark Following 26% Share Price Bounce
Standard BioTools Inc. (NASDAQ:LAB) recently experienced a 26% share price bounce, bringing its price-to-sales (P/S) ratio of 3x in line with the broader U.S. Life Sciences industry median. This follows a year where the stock was still down 23%, despite the recent gain. The company's revenue growth metrics, including a 34% gain in the last year and a 37% rise over three years, align with industry forecasts, suggesting shareholders are comfortable with its current valuation.
Standard BioTools Inc. (LAB) reports earnings
Standard BioTools Inc. (LAB) reported its Q4 2024 earnings, revealing a 64% increase in total revenue to $174.4 million, largely due to its merger with SomaLogic. Despite this growth, the company incurred a net loss of $138.9 million, attributed to increased operating expenses post-merger, alongside a bargain purchase gain from the SomaLogic acquisition and another acquisition of Sengenics Corporation. The company ended the year with strong cash reserves and a focus on expanding its proteomics offerings.
LAB Stock Price and Chart — NASDAQ:LAB
This article provides a comprehensive overview of Standard BioTools Inc. (LAB) stock performance, financial data, and analyst insights. It includes real-time stock price, historical performance metrics across various periods, key financial statistics, company information, and an aggregated view of analyst ratings and forecasts. The article also lists related ETFs and frequently asked questions about the company's stock.
